786596-55-2

Upstream product

• 5345-42-6 1-methoxy-3-methyl-2-nitro-benzene 
• 85598-12-5 4-bromo-3-methyl-2-nitro-phenol 
• 4920-77-8 3-methyl-2-nitrophenol 
• 85598-13-6 1-bromo-4-methoxy-2-methyl-3-nitro-benzene 

Downstream Products

• 1186421-69-1 3-[3-(7-methoxy-1H-indazol-4-yl)-2-pyridin-4-ylpyrazolo[1,5-a]pyrimidin-7-yl]-N,N-dimethylbenzenesulfonamide 
• 1186422-15-0 7-methoxy-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-indazole 
• 938062-01-2 4-bromo-7-methoxy-1H-indazole 

Relevant academic research and scientific papers

QUINAZOLINE COMPOUNDS

The present invention relates to quinazoline compounds of formula I that function as inhibitors of RET (rearranged during transfection) kinase enzyme activity: (Formula (I)) wherein X, R1, R2, R3, R4, R5, R6 and R7 are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which RET kinase activity is implicated.

PHENYLSULFONAMIDE-SUBSTITUTED, PYRAZOLO[1, 5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF

Phenylsulfonamide substituted, pyrazolo[1,5-a]pyrimidines are described. The compounds of the invention selectively inhibit Raf kinase activity and are useful for treating disorders associated with Raf kinases. Formula (I)

3-Amino-1-arylpropyl indoles and aza-substituted indoles and uses thereof

The present invention provides compounds of the formula: or pharmaceutically acceptable salts, solvates or prodrugs thereof, wherein p, Ar, R1, R2, R3, Ra, Rb, Rc, Rd and Re are defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the compounds.